Somewhat Favorable News Coverage Somewhat Unlikely to Affect Novogen Limited (NVGN) Stock Price

News articles about Novogen Limited (NASDAQ:NVGN) have trended somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novogen Limited earned a news impact score of 0.13 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 44.1639541610912 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Novogen Limited (NASDAQ NVGN) opened at $2.95 on Wednesday. Novogen Limited has a 12-month low of $1.63 and a 12-month high of $7.60.

NVGN has been the subject of several recent research reports. Zacks Investment Research upgraded shares of Novogen Limited from a “sell” rating to a “hold” rating in a research report on Tuesday, September 5th. ValuEngine lowered shares of Novogen Limited from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Week Herald and is the property of of Week Herald. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://weekherald.com/2017/11/15/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-novogen-limited-nvgn-stock-price.html.

Novogen Limited Company Profile

Novogen Limited (Novogen) is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications.

Insider Buying and Selling by Quarter for Novogen Limited (NASDAQ:NVGN)

Receive News & Ratings for Novogen Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply